Vertex Pharmaceuticals Inc. (VRTX)

176.23
NASDAQ : Health Technology
Prev Close 177.72
Day Low/High 175.38 / 180.25
52 Wk Low/High 151.80 / 195.81
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 257.04M
Market Cap 45.68B
EPS 8.20
P/E Ratio 20.81
Div & Yield N.A. (N.A)
Vertex To Present At The Credit Suisse Healthcare Conference On November 10

Vertex To Present At The Credit Suisse Healthcare Conference On November 10

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 10 th at 11:30 a.

Analysts' Actions -- Vertex, LinkedIn, BE/Aerospace, DreamWorks, Starbucks

Analysts' Actions -- Vertex, LinkedIn, BE/Aerospace, DreamWorks, Starbucks

Here are Friday's top research calls, including new ratings at LinkedIn, BE/Aerospace, DreamWorks, Starbucks, Vertex and more.

Vertex Reports Third Quarter 2015 Financial Results

Vertex Reports Third Quarter 2015 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2015.

Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a "perilous reversal" (up big yesterday but down big today) candidate

3 Stocks Underperforming Today In The Health Care Sector

3 Stocks Underperforming Today In The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector lower today.

Vertex And CRISPR Therapeutics Establish Collaboration To Use CRISPR-Cas9 Gene Editing Technology To Discover And Develop New Treatments For Genetic Diseases

Vertex And CRISPR Therapeutics Establish Collaboration To Use CRISPR-Cas9 Gene Editing Technology To Discover And Develop New Treatments For Genetic Diseases

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics today announced that the two companies have entered into a strategic research collaboration focused on the use of CRISPR's gene editing technology,...

3 Stocks Pulling The Drugs Industry Downward

3 Stocks Pulling The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Vertex To Announce Third Quarter 2015 Financial Results On October 28

Vertex To Announce Third Quarter 2015 Financial Results On October 28

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2015 financial results on Wednesday, October 28, 2015 after the financial markets close.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Vertex Pharmaceuticals Incorporated -- VRTX

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Vertex Pharmaceuticals Incorporated -- VRTX

Levi & Korsinsky announces it has commenced an investigation of Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) concerning possible breaches of fiduciary duty by its Board of Directors.

Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments

Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments

Advancing the new Vertex drugs into the clinic should also quiet, but not eliminate, investor concerns about competitors closing the gap on the company's market-dominant position in cystic fibrosis treatments.

Vertex Announces Significant Progress In Its Development Efforts To Treat The Cause Of Cystic Fibrosis In The Vast Majority Of People With The Disease

Vertex Announces Significant Progress In Its Development Efforts To Treat The Cause Of Cystic Fibrosis In The Vast Majority Of People With The Disease

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced significant progress in its development efforts to treat the underlying cause of cystic fibrosis (CF) for the vast majority of people with the...

Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices

Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices

Rising drug prices are getting increased scrutiny from lawmakers and presidential hopefuls, but here are nine stocks positioned well.

Analysts' Actions -- Google, Gilead, AIG and More

Analysts' Actions -- Google, Gilead, AIG and More

Here are Friday's top research calls on Google, Gilead, AIG and more.

10 Worst Health Care Stocks in the Third Quarter

10 Worst Health Care Stocks in the Third Quarter

Here are the worst health care stocks.

Strong On High Relative Volume: Vertex Pharmaceuticals (VRTX)

Strong On High Relative Volume: Vertex Pharmaceuticals (VRTX)

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a strong on high relative volume candidate

Vertex Receives CHMP Positive Opinions For ORKAMBI™ (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) In The European Union

Vertex Receives CHMP Positive Opinions For ORKAMBI™ (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) In The European Union

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Union Committee for Medicinal Products for Human Use (CHMP) issued a positive Opinion recommending Marketing Authorization of...

3 Stocks Dragging The Health Care Sector Downward

3 Stocks Dragging The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan

Analysts Say Buy Select Biotech Stocks Ahead Of Clinton Drug Plan

Analysts at research firms Jefferies and Piper Jaffray are recommending select biotech stocks that they view as buys amid the weakness in the space.

Clinton Drug Plan Cuts Market Exclusivity, Sets Mandatory R&D Spending

Clinton Drug Plan Cuts Market Exclusivity, Sets Mandatory R&D Spending

If Clinton's proposal is implemented, biotech companies would have less time to generate profits from their expensive biologic drugs before other companies could enter the market with cheaper copies.

Roof Leaker To Watch: Vertex Pharmaceuticals (VRTX)

Roof Leaker To Watch: Vertex Pharmaceuticals (VRTX)

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate

3 Stocks Underperforming Today In The Drugs Industry

3 Stocks Underperforming Today In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Analysts' Actions -- Marvell, Dow Chemical, Other Calls

Analysts' Actions -- Marvell, Dow Chemical, Other Calls

Here are Monday's top research calls, including downgrades for Alexion, Marvel and Sirona Dental.

Vertex To Present At The Morgan Stanley Healthcare Conference On September 16

Vertex To Present At The Morgan Stanley Healthcare Conference On September 16

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 16 th at...

Vertex Pharmaceuticals (VRTX) Is Strong On High Volume Today

Vertex Pharmaceuticals (VRTX) Is Strong On High Volume Today

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a strong on high relative volume candidate

Biotech Stocks Recover From Early-Morning Flash Crash

Biotech Stocks Recover From Early-Morning Flash Crash

The iShares Nasdaq Biotechnology Index (IBB), the most closely followed biotech sector index, is down less than 1% after a deep plunge at Monday's open.

Vertex Awards Two Boston Public High School Students The Vertex Science Leaders Scholarship To The University Of Massachusetts

Vertex Awards Two Boston Public High School Students The Vertex Science Leaders Scholarship To The University Of Massachusetts

Vertex and the University of Massachusetts (UMass) today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year scholarship to pursue their education in Science, Technology,...

50 Stocks to Watch for Good Plays: Jim Cramer's Best Blogs

50 Stocks to Watch for Good Plays: Jim Cramer's Best Blogs

Catch up on Jim Cramer's ideas from this past week as he discusses eight groups to watch for good plays and mentions about 50 stocks among them.

Expect Bumpy Ride When 'Unicorn' Tech Bubble Pops, Says Avalon Founder

Expect Bumpy Ride When 'Unicorn' Tech Bubble Pops, Says Avalon Founder

Kevin Kinsella says valuations of 'unicorn' companies have become outlandish. These start-up technology companies blessed with billion-dollar valuations better buckle up.

Stocks With Significant High Activity: the First Four Groups

There are some good buying ideas among these stocks.

TheStreet Quant Rating: B (Buy)